Final Health Reform Bill Looks Positive For Pharma Firms
Executive Summary
It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result
You may also be interested in...
Coverage, Courts And Congress: News In Brief
Congress again seeks to restrict reverse settlements: Sen. Herb Kohl, D-Wis., proposed an amendment to a tax bill that would amend the Federal Trade Commission Act so that agreements between brand and generic companies to settle patent infringement claims are presumed to have anticompetitive effects if the ANDA filer receives anything of value and agrees to limit or forgo research, development or sales of its product. The presumption shall not apply if the parties "demonstrate by clear and convincing evidence that the precompetitive benefits of the agreement outweigh the anticompetitive effects of the agreement." Kohl introduced the amendment, SA 4332, on June 9 for inclusion in the American Jobs and Closing Tax Loopholes Act, H.R. 4213. Legislators had previously pushed for a similar amendment to render such deals illegal in the health care reform bill (1"The Pink Sheet," March 22, 2010)